RecruitingPhase 1NCT07228364

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Studying Autosomal dominant polycystic kidney disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AstraZeneca
Intervention
AZD1613 - Part A(drug)
Enrollment
40 enrolled
Eligibility
18-65 years · All sexes
Timeline
20252027

Study locations (15)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07228364 on ClinicalTrials.gov

Other trials for Autosomal dominant polycystic kidney disease

Additional recruiting or active studies for the same condition.

See all trials for Autosomal dominant polycystic kidney disease

← Back to all trials